On June 1, 2020 BERG, a clinical-stage biotech company that uses Artificial Intelligence (AI) to research diseases and develop innovative treatments, reported results from a Phase 1 clinical study of its investigational drug, BPM 31510 (novel ubidecarenone formulation) in glioblastoma (GBM) (Press release, Berg, JUN 1, 2020, View Source [SID1234560741]). The study, presented at the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), highlights safety, tolerability and the impact of BPM 31510-IV influence on metabolism in patients, supporting planned Phase 2 clinical development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"At BERG, we understand the toll cancer takes not only on a patient, but also their loved ones, and we want to lead in the battle to fight the disease," said Dr. Niven R. Narain, BERG Co-founder, President and Chief Executive Officer. "BPM 31510 is a unique therapeutic modality targeting cell metabolism that is consistent with our proprietary Interrogative Biology platform. We are excited at the opportunities the findings will have in refining clinical development among multiple cancer indications, especially in brain cancers."
GBM is a destructive type of brain cancer often acknowledged for its steep morbidity and mortality rates. There are few effective treatment options available in the marketplace, thus substantiating the urgent need for novel therapeutic approaches to improve outcomes for this disease. BPM 31510 is a unique therapeutic modality which specifically targets cell metabolism and shifts the cancer’s glycolytic dependency toward mitochondrial oxidative phosphorylation. When applied, it induces oxidative stress and causes cell death, specifically of cancer cells. BPM 31510 serves as particularly relevant indication for GBM’s glycolytic dependency.
The study was led by Seema Nagpal, M.D. Clinical Associated Professor of Neurology & Neurological Sciences, and Lawrence Recht, M.D., Professor of Neurology & Neurological Sciences, both of Stanford University School of Medicine, with other Stanford Medicine researchers and in collaboration with BERG.
Details of the BERG presentation:
This Poster is available to registered 2020 ASCO (Free ASCO Whitepaper) Virtual Scientific Program attendees and can be viewed at:
View Source
In its commitment to serve patients afflicted with cancer, BERG has collaborated on other projects with leading institutions, like MD Anderson Cancer Institute (clinical trials) and Harvard/BIDMC (Project Survival), among others.